Gilead Sciences

Leadership as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Gilead Sciences: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 68 in our ClinicalTrials.gov registers · 6 in the EU register

Showing 10 of 68, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 54 compounds

EU trials register (CTIS) 6 authorised or ongoing

• Study of GS-5319 in Adults With Solid Tumors2025-522397-36-00 · Phase I · Ongoing
• A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens2025-524336-19-00 · Phase III · Ongoing
• A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy2025-524335-39-00 · Phase III · Ongoing
• A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).2025-523984-39-00 · Phase II · Authorised
• Study of GS-2426 in Participants With Advanced Solid Tumors2026-526264-20-00 · Phase I · Authorised
• A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)2025-522517-35-00 · Phase I/II · Ongoing

Medicine shortages 4 in the FDA list

• Emtricitabine Oral SolutionUS (FDA) · resolved · updated 17 Jun 2026
• Emtricitabine CapsuleUS (FDA) · resolved · updated 17 Jun 2026
• Idelalisib TabletUS (FDA) · resolved · updated 7 Apr 2026
• Cobicistat TabletUS (FDA) · resolved · updated 7 Oct 2025

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 15 of its medicines · 14 current

• Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)NICE TA1089 · Terminated (no company submission) · 13 Aug 2025
• Remdesivir and tixagevimab plus cilgavimab for treating COVID-19NICE TA971 · Optimised, Not recommended · 8 May 2024
• Bulevirtide for treating chronic hepatitis DNICE TA896 · Optimised · 7 Jun 2023
• Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesNICE TA819 · Recommended · 17 Aug 2022
• Idelalisib for treating refractory follicular lymphomaNICE TA604 · Not recommended · 2 Oct 2019
• Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis CNICE TA507 · Optimised · 21 Feb 2018
• Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)NICE TA469 · Terminated (no company submission) · 23 Aug 2017
• Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)NICE TA435 · Terminated (no company submission) · 22 Mar 2017

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Gilead Sciences): founded 1987, headquarters Foster City, website gilead.com. Wikidata Q663596 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Gilead Sciences; Gilead Sciences Inc.; Gilead Sciences Ireland UC; Gilead Sciences Ireland Unlimited Company; Gilead Sciences, Inc.; GILEAD and 1 more. Spot a wrong match? Tell us.

From the annual reports Gilead Sciences, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 4 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Gilead Sciences, Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.